Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài:Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. | Available online http content 7 3 R644 Research article Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis systematic review and meta-analysis of information from company clinical trial reports R Andrew Moore1 Sheena Derry1 Geoffrey T Makinson2 and Henry J McQuay1 1Pain Research and Nuffield Department of Anaesthetics University of Oxford Oxford Radcliffe NHS Trust Oxford UK 2Department of Outcomes Research and Evidence-based Medicine Pfizer Ltd Walton Oaks Surrey UK Corresponding author R Andrew Moore Received 24 Nov 2004 Revisions requested 4 Jan 2005 Revisions received 21 Jan 2005 Accepted 28 Jan 2005 Published 24 Mar 2005 Arthritis Research Therapy 2005 7 R644-R665 DOI 86 ar1 704 This article is online at http content 7 3 R644 2005 Moore et al. licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract The objective was to improve understanding of adverse events occurring with celecoxib in the treatment of osteoarthritis and rheumatoid arthritis. Data were extracted from company clinical trial reports of randomised trials of celecoxib in osteoarthritis or rheumatoid arthritis lasting 2 weeks or more. Outcomes were discontinuations all cause lack of efficacy adverse event gastrointestinal adverse event endoscopically detected ulcers gastrointestinal or cardio-renal events and major changes in haematological parameters. The main comparisons were celecoxib all doses versus placebo paracetamol acetaminophen 4 000 mg daily rofecoxib 25 mg daily or nonsteroidal anti-inflammatory drugs NSAIDs naproxen diclofenac ibuprofen and loxoprofen . For NSAIDs celecoxib was compared both at all .
